Sun Pharmaceutical climbs on getting USFDA’s nod for LEQSELVI tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Sun Pharmaceutical Industries is currently trading at Rs. 1704.80, up by 39.60 points or 2.38% from its previous closing of Rs. 1665.20 on the BSE.
The scrip opened at Rs. 1675.00 and has touched a high and low of Rs. 1712.00 and Rs. 1665.20 respectively. So far 103105 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,712.00 on 26-Jul-2024 and a 52 week low of Rs. 1069.00 on 31-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1712.00 and Rs. 1558.10 respectively. The current market cap of the company is Rs. 409806.41 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.51% and 9.02% respectively.
Sun Pharmaceutical Industries has received U.S. Food and Drug Administration’s (USFDA) approval for LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia areata affects around 700,000 people in the United States, and 300,000 have severe alopecia areata. Alopecia often leads patients to self-treat before seeking professional help, driven by dissatisfaction with the slow progress of existing treatments.
Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the collapse of immune privilege, leading to the immune system targeting the hair follicles and causing sudden hair loss on the scalp, face and sometimes other areas of the body. LEQSELVI is a new, twicedaily oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2. As a JAK inhibitor, LEQSELVI interrupts the pathways thought to contribute to hair loss in severe alopecia areata.
The approval is based on data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trials THRIVE-AA1 and THRIVE-AA2, which enrolled a total of 1,220 patients with alopecia areata who had at least 50% scalp hair loss as measured by Severity of Alopecia Tool (SALT) for more than six months. Data were also collected from two open-label, long-term extension trials in which patients were eligible to enroll upon completion of the 24-week trials.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
